Anti-IL22 Recombinant Antibody (Fezakinumab) (CAT#: TAB-748)
Recombinant human monoclonal antibody expressed in CHO binding to human IL22. Fezakinumab is a human monoclonal antibody against interleukin-22, designed for the treatment of psoriasis and rheumatoid arthritis.
Specific Inquiry
SDS-PAGE
Figure 1 Anti-IL22 Recombinant Antibody (TAB-748) in SDS-PAGE
Lane 1: Reduced
Lane 2: Non-reduced
SEC-HPLC
Figure 2 Anti-IL22 Recombinant Antibody (TAB-748) in HPLC
The purity of TAB-748 was greater than 95% as determined by SEC-HPLC.
Specifications
- Immunogen
- The details of the immunogen for this antibody are not available.
- Host Species
- Human
- Derivation
- Human
- Type
- IgG1 - lambda
- Species Reactivity
- Human
- Applications
- Suitable for use in IF, IP, Neut, FuncS, ELISA, FC, IHC and most other immunological methods.
- CAS
- 1007106-86-6
- Generic Name
- fezakinumab
- UNII
- 0S77U25XZ3
- MW
- 143.87 kDa
- Related Disease
- Inflammatory conditions, acute and chronic
Product Property
- Purity
- >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
- Storage
- Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.
Target
- Alternative Names
- fezakinumab;1007106-86-6;ILV-094;IL22;interleukin 22;interleukin-22;IL 10 related T cell derived inducible factor;IL 21;IL 22;IL D110;IL TIF;ILTIF;MGC79382;MGC79384;TIFa;TIFIL 23;zcyto18;cytokine Zcyto18;IL-10-related T-cell-derived inducible factor;IL-10
- Gene ID
- 50616
- UniProt ID
- Q9GZX6
Related Resources
Please refer to Fezakinumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Fezakinumab.
Inflammatory Bowel Diseases
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Fezakinumab"
Afuco™ Anti-IL22 ADCC Recombinant Antibody (Fezakinumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human monoclonal antibody expressed in CHO binding to human IL22. Fezakinumab is a human monoclonal antibody against interleukin-22, designed for the treatment of psoriasis and rheumatoid arthritis.
See other products for "IL22"
Select a product category from the dropdown menu below to view related products.
Please select product type
Single-domain Antibody
Mouse Antibody
Neutralizing Antibody
Rabbit Monoclonal Antibody
Recombinant Antibody
scFv Fragment Antibody
Fab Fragment Antibody
ADCC Enhanced Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NAB-1442-sdAb | Recombinant Anti-Human IL22 VHH Single Domain Antibody | WB, ICC, ChiP, FA, ELISA | Llama VHH |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for TAB-748. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
Application: WB, ELISA, IP, FC, FuncS, Neut, IF
Application: WB, FuncS, IF, Neut, ELISA, FC, IP
Application: FuncS, IF, Neut, ELISA, FC, IP, ICC
Application: WB, IF, FuncS
Application: ELISA
Application: WB, ELISA, FuncS, IB, FC, SPR, Apop
Application: Neut, IHC, Activ, FuncS, IF, ELISA
Application: ELISA, Activ, Block
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
